---
ID: P102
Title: Clinical Trial Matching & Eligibility AI
Registry: CLAI-OS Precision Engine (P-series)
License: Open documentation release (prompt body withheld for validation)
Version: 1.0.0
Author: Dr. Christabel Odeta — SAVANT FRAMEWORK · CLAI-OS · AEGIS-GLOBAL
Last Updated: 2026-10-12
---

# P102: Clinical Trial Matching & Eligibility AI

## Abstract

Clinical trial access remains one of the most inequitable domains in medicine, with enrollment frequently determined by geography, institutional affiliation, socioeconomic status, or physician awareness rather than biologic eligibility. P102 transforms trial recruitment from institution-centered discovery into patient-centered matching through automated eligibility parsing, reverse matching, molecular stratification, geographic optimization, and pre-screening automation.

> Prompt body: WITHHELD. This is an open documentation release — abstract, methodology, and merits — published so the design can be examined and validated.

## Methodology

**Design objectives**

- NLP eligibility parsing that extracts structured variables (age, stage, histology, biomarkers, prior lines, ECOG status, organ function, pregnancy status, washout periods, comorbid exclusions) from unstructured protocol text via named entity recognition, ontology mapping, and semantic normalization.
- Reverse-matching framework (patient profile to ranked trial list) ordered by eligibility probability, geographic accessibility, scientific relevance, therapeutic novelty, expected toxicity, and travel feasibility.
- Molecular matching layer (EGFR, ALK, BRAF, HER2, NTRK, MSI, TMB, HBB, FLT3, NPM1) with basket trial routing, umbrella trial stratification, and adaptive trial recognition.
- Automated pre-screening packet generation (molecular report summary, staging confirmation, performance status history, laboratory trends, medication reconciliation, imaging timelines, pathology abstraction) intended to reduce enrollment friction from weeks to minutes.
- Sickle-cell disease trial access (gene therapy trials, allogeneic transplant studies, vaso-occlusive crisis intervention protocols, renal medullary carcinoma basket trials, curative-intent cellular therapies) with equity enforcement: geographic exclusion detection, remote enrollment pathways, and decentralized trial integration.

**Methodological innovation**

- Sub-60-second matching: real-time trial identification designed to reduce time-to-enrollment from months to minutes.
- Federated trial intelligence: cross-region synchronization across North America, Europe, Africa, Asia-Pacific, and Latin America, with language normalization and regulatory harmonization mapping.
- Equity enforcement layer: automatic bias detection across geography, insurance, language, travel burden, and socioeconomic access failure, with mitigation through teletrial architecture and decentralized integration.

**Key performance indicators**

- Trial matching time (patient-to-first-contact)
- Enrollment conversion rate
- Geographic diversity of enrolled patients
- Molecular match accuracy
- Sickle-cell-specific trial access rate
- Protocol deviation reduction
- Regulatory compliance maintenance

**Integration**

- Upstream: P91 (Genomic Variant Actionability Arbiter) for molecular eligibility; P103 (Real-World Evidence & Digital Twin Generator) for synthetic control arm availability.
- Downstream: P105 (Data Sovereignty & Federated Learning Governance) for consent and governance; P109 (Health Economics & Value-Based Care Optimizer) for trial cost-effectiveness.

## Merits

- Democratizes clinical-trial access using NLP-based eligibility parsing and real-time patient-trial alignment.
- Reduces inequity in trial enrollment by matching on biologic eligibility rather than geography or institutional affiliation.
- Accelerates translational medicine by compressing the recruitment interval.
- Provides global oncology collaboration infrastructure with regulatory harmonization mapping.
- Extends trial access to sickle-cell gene therapy and curative-intent studies, historically among the least accessible.

## Guidance for Use

This document records the design intent and scientific rationale of P102 (Clinical Trial Matching & Eligibility AI) as published in the CLAI-OS Tier III (Savant Precision Engine, P91–P110) compendium. The executable prompt body is withheld; nothing in this file is sufficient to operate the module. The material is released openly so that the design can be examined, critiqued, and independently validated.

Appropriate use:

- Scientific review, replication design, and methodological critique by researchers and validation groups.
- Reference for integration planning across the P-series registry.
- Citation in scholarly or institutional work describing the CLAI-OS Precision Engine.

Limitations:

- This is not a medical device, a clinical decision-support product, or a standard of care. Nothing in this document may be used to direct diagnosis, treatment, dosing, or triage for any patient.
- Genomic and oncology statements reflect only the claims made in the canonical compendium; publication of this documentation does not constitute independent clinical validation.
- Eligibility parsing and matching outputs are research tooling; enrollment decisions remain with investigators, sponsors, and treating physicians under applicable regulatory frameworks.

---

C0 informational classification; confers no clinical, legal, financial, or safety authority.
